Caraco Pharmaceutical (CPD) to Market Extended Phenytoin Sodium Capsules for Sun Pharma
More News related to CPD
- Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
- Caraco Pharmaceutical Labs (CPD) Posts Q3 EPS of $0.17
- Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
- Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
- Morning Movers 9/30: HOKU, ICCC, VSR, CFW, DSCO Higher; CIT, HX, RGN, ICON, APAB, RMTI Lower
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) will market Extended Phenytoin Sodium Capsules, USP 100mg (Phenytoin ER) on behalf of Sun Pharmaceutical Industries, Ltd. Sun Pharma recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Phenytoin ER.
Phenytoin ER is an anticonvulsant drug. It is useful in the treatment of seizures related to epilepsy and neurosurgery. This new product is the bioequivalent to Dilantin Kapseals(R), a registered trademark of Parke Davis,(Pfizer). According to IMS Data, Phenytoin ER generic and brand products combined have annual sales of approximately $170 million.
Related Categories
FDAStocks Mentioned
-0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
